Log in

Diabetes: Sanofi ties a research partnership with a British start-up

The French group Sanofi has partnered research and an option for a licensing agreement with the Scottish Exscientia startups in the field of metabolic diseases such as diabetes, said Tuesday the sapling in a statement.

Exscientia specializes in the discovery and drug design through the use of artificial intelligence.

In this partnership, the company will bring its platform identification and validation pair combinations of drug targets before selecting those that seem most promising for Sanofi, the statement said.

Subsequent trials, preclinical testing will be supported by Sanofi, which can exercise the license option.

The agreement includes an initial research payment and milestone payments. Overall, the amount potentially payable by Sanofi amounted to 250 million, the statement said.

a3p-100pxhaut logo


Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb here )

  group    administrators A3P
& Project Managers

letter   newsletter A3P